Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis

Luca Campora Department of Animal Pathology Faculty of Veterinary Medicine, University of Pisa, 56124 Pisa, Italy.

Search for other papers by Luca Campora in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Vincenzo Miragliotta Department of Animal Pathology Faculty of Veterinary Medicine, University of Pisa, 56124 Pisa, Italy.

Search for other papers by Vincenzo Miragliotta in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Emanuele Ricci Department of Animal Pathology Faculty of Veterinary Medicine, University of Pisa, 56124 Pisa, Italy.

Search for other papers by Emanuele Ricci in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Luigia Cristino Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy.

Search for other papers by Luigia Cristino in
Current site
Google Scholar
PubMed
Close
 Biol D, PhD
,
Vincenzo Di Marzo Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Naples, Italy.

Search for other papers by Vincenzo Di Marzo in
Current site
Google Scholar
PubMed
Close
 Chem D, PhD
,
Francesco Albanese Clinica Veterinaria L'Arca, Vico Cacciottoli 46/47, 80129 Naples, Italy.

Search for other papers by Francesco Albanese in
Current site
Google Scholar
PubMed
Close
 DVM
,
Maria Federica della Valle Science Information and Documentation Centre (CeDIS), Innovet Italia SRL, Via Egadi 7, 20144 Milano, Italy.

Search for other papers by Maria Federica della Valle in
Current site
Google Scholar
PubMed
Close
 MSc
, and
Francesca Abramo Department of Animal Pathology Faculty of Veterinary Medicine, University of Pisa, 56124 Pisa, Italy.

Search for other papers by Francesca Abramo in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

Objective—To determine the distribution of cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) in skin (including hair follicles and sweat and sebaceous glands) of clinically normal dogs and dogs with atopic dermatitis (AD) and to compare results with those for positive control samples for CB1 (hippocampus) and CB2 (lymph nodes).

Sample—Skin samples from 5 healthy dogs and 5 dogs with AD and popliteal lymph node and hippocampus samples from 5 cadavers of dogs.

Procedures—CB1 and CB2 were immunohistochemically localized in formalin-fixed, paraffin-embedded sections of tissue samples.

Results—In skin samples of healthy dogs, CB1 and CB2 immunoreactivity was detected in various types of cells in the epidermis and in cells in the dermis, including perivascular cells with mast cell morphology, fibroblasts, and endothelial cells. In skin samples of dogs with AD, CB1 and CB2 immunoreactivity was stronger than it was in skin samples of healthy dogs. In positive control tissue samples, CB1 immunoreactivity was detected in all areas of the hippocampus, and CB2 immunoreactivity was detected in B-cell zones of lymphoid follicles.

Conclusions and Clinical Relevance—The endocannabinoid system and cannabimimetic compounds protect against effects of allergic inflammatory disorders in various species of mammals. Results of the present study contributed to knowledge of the endocannabinoid system and indicated this system may be a target for treatment of immune-mediated and inflammatory disorders such as allergic skin diseases in dogs.

Abstract

Objective—To determine the distribution of cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) in skin (including hair follicles and sweat and sebaceous glands) of clinically normal dogs and dogs with atopic dermatitis (AD) and to compare results with those for positive control samples for CB1 (hippocampus) and CB2 (lymph nodes).

Sample—Skin samples from 5 healthy dogs and 5 dogs with AD and popliteal lymph node and hippocampus samples from 5 cadavers of dogs.

Procedures—CB1 and CB2 were immunohistochemically localized in formalin-fixed, paraffin-embedded sections of tissue samples.

Results—In skin samples of healthy dogs, CB1 and CB2 immunoreactivity was detected in various types of cells in the epidermis and in cells in the dermis, including perivascular cells with mast cell morphology, fibroblasts, and endothelial cells. In skin samples of dogs with AD, CB1 and CB2 immunoreactivity was stronger than it was in skin samples of healthy dogs. In positive control tissue samples, CB1 immunoreactivity was detected in all areas of the hippocampus, and CB2 immunoreactivity was detected in B-cell zones of lymphoid follicles.

Conclusions and Clinical Relevance—The endocannabinoid system and cannabimimetic compounds protect against effects of allergic inflammatory disorders in various species of mammals. Results of the present study contributed to knowledge of the endocannabinoid system and indicated this system may be a target for treatment of immune-mediated and inflammatory disorders such as allergic skin diseases in dogs.

All Time Past Year Past 30 Days
Abstract Views 589 0 0
Full Text Views 15563 12865 421
PDF Downloads 1844 663 47
Advertisement